PHARMACY

Purdue Pharma names president and CEO

BY Michael Johnsen

STAMFORD, Conn. — Purdue Pharma on Monday named Mark Timney as president and CEO.

"We found a proven leader in Mark Timney," said Raymond Sackler, co-founder and board member of Purdue. "I am confident that his capabilities and experience, coupled with Purdue’s culture of excellence, will grow our business and strengthen our healthcare industry leadership." 

Timney brings more than 20 years of pharmaceutical sales and marketing experience to Purdue, including success in designing and executing strategies to achieve market leadership. Prior to joining Purdue, he was president of Merck US, where he managed sales and marketing, managed markets and payers.  

With Timney’s guidance, Purdue will continue advancing research and development initiatives and pioneering new commercial models. 

Before coming to the United States, Timney served for seven years as Merck’s country manager in Korea and then Japan. Prior to that, he held leadership positions for more than four years at Merck Australia. Before joining Merck, he spent eight years in sales and marketing at a number of multinational pharmaceutical companies, including Zeneca in New Zealand, ICI Pharmaceuticals in Australia and Roussel Labs in the United Kingdom. 

Timney succeeds John Stewart, who has retired from Purdue.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Walgreens Infusion Services selected as preferred provider for Makena

BY Michael Johnsen

DEERFIELD, Ill. — Walgreens Infusion Services on Monday announced that it has been selected as the preferred provider of home administration services for Makena (hydroxyprogesterone caproate injection), the only FDA-approved medication to help reduce the risk of preterm birth for clinically indicated patients. Makena is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.

The new initiative, Makena @Home, creates access to weekly administration of the only FDA-approved medication for this indication in the home setting when covered by the patient’s insurance, providing an important option for patients and their healthcare providers. The program provides home administration of Makena by trained nurses, along with patient assessment and personalized care plan development, reimbursement/coverage coordination for home administration of therapy and scheduling and administrative support for patients.

“Makena is an important treatment for women at risk for recurrent preterm birth,” said Paul Mastrapa, president of Walgreens Infusion Services. “Makena @Home allows our expert multidisciplinary teams to care for patients in a comfortable and convenient location for them. We’re proud to add Makena @Home to the services we provide to patients in their homes and at alternate treatment sites nationwide each day.”

“Selecting Walgreens Infusion Services for Makena @Home gives us confidence that patients who need their weekly injections of FDA-approved Makena administered at home are receiving high-quality care,” said Greg Divis, CEO of K-V Pharmaceutical Company. “We’re excited to collaborate with a well-respected and widely recognized partner in Walgreens to provide this important option for the patients and providers we work with every day.”

Makena is administered by a healthcare provider as a single dose into the hip area (upper outer area of the buttocks) once a week, rotating sides each week. The goal of a healthy pregnancy is to deliver at term — at least 37 weeks of pregnancy. Makena is the only FDA-approved treatment that may help patients who have delivered preterm in the past stay pregnant longer.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

ScriptCycle expands solutions for retail pharmacies

BY Ryan Chavis

ASHEVILLE, N.C. — ScriptCycle, a technology company that serves pharmacies and patients, will launch its comprehensive cash solutions for retail pharmacies at the NACDS Regional Conference in February. The products aim to help pharmacies address challenges related to their cash prescription business, the company said.

ScriptCycle said its business model has produced average per-store savings of $7,000 to $12,000 per year.

"Our business model is simple, really. When pharmacies save money, patients save money," said Phil Trunnell, CEO of Scriptcycle. "Scriptcycle¹s focus is to provide pharmacy solutions that increase margins and translate patient value into patient loyalty. We look forward to explaining our company to more pharmacy chains at the NACDS Regional Conference."

The NACDS Regional Conference will be held in Naples, Fla., from Feb. 2 to Feb. 5 at the Ritz Carlton. ScriptCycle will be available for meetings at table No. 121.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?